Two days following tumor detection, mice were enrolled into one of four treatment groups. Control Rat IgG (BioXCell) and αPDL1 (clone 10 F.9G2, BioXCell) antibodies were given intra peritoneally (100 μg/mouse) every other day, αCTLA4 antibody (clone UC10–4 F10–11, BioXCell) was given i.p. (100 μg/mouse) every three days twice. For the long-term treatment, mice were treated for two weeks, and for the mass cytometry experiment, mice were treated for one week. For the macrophage-depletion experiments, anti-CSF1R antibody (#BE0213, clone AFS98, BioCXell) was administered (400 μg/mouse) thrice a week for two weeks (24 (link),25 (link)).
αctla4 antibody clone uc10 4 f10 11
Manufactured by BioXCell
The αCTLA4 antibody (clone UC10-4F10-11) is a laboratory reagent used for research purposes. It is a monoclonal antibody that binds to the CTLA4 (cytotoxic T-lymphocyte-associated protein 4) receptor on T cells. The core function of this antibody is to facilitate the study of CTLA4 and its role in immune system regulation.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using αctla4 antibody clone uc10 4 f10 11
1
Tumor Immunotherapy Treatment Regimen
2
Combination Immunotherapy for Tumor Treatment
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Treatment was initiated on day 4 post tumor inoculation with the following regimens for each drug (illustrated in Figure 1 A). αCTLA-4 antibody (clone UC10-4 F10-11, Bio-X-Cell) was given i.p. on day 4, 7 and 10 at a dose of 100 μg/mouse. αPD-L1 antibody (clone 10 F.9G2, Bio-X-Cell) was given i.p. (100 μg/mouse) every other day starting on day 4 ending on day 16 post tumor inoculation. IDOi (INCB23843, Incyte Corporation) was dissolved in 0.5% methylcellulose and administered at 300 mg/kg po QD on a 5 days on/2 days off schedule starting on day 4 [35 (link),51 (link)]. In the case of functional experiments with an earlier endpoint, treatment regimens were carried out as described until the day of T cell analysis. For delayed therapy the same treatment scheme was applied starting on day 7 post-tumor inoculation, when tumors were palpable.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!